Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.

@article{Furukawa2006EfficacyAS,
  title={Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.},
  author={Koichi Furukawa and Yoshinori Ito and Shunji Takahashi and Masataka Sawaki and Nobuyuki Mizunuma and Noboru Horikoshi and Fujio Kasumi and Futoshi Akiyama and Goi Sakamoto and Kiyonori Furukawa and Takashi Tajiri and Kiyohiko Hatake},
  journal={Breast cancer},
  year={2006},
  volume={13 4},
  pages={329-33}
}
BACKGROUND In breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer. PATIENTS AND METHODS Combination chemotherapy was given to patients with HER-2 overexpressing metastatic breast cancer. All patients had previously received one or more chemotherapy treatments. Patients… CONTINUE READING
3 Extracted Citations
18 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…